Primary Myelofibrosis (PMF) Completed Phase 2 Trials for Momelotinib (DB11763)

Also known as: Primary Myelofibrosis / Primary Myelofibrosis (MF) / Myelofibrosis (PMF) / Myelofibrosis, Primary / PMF / Osteomyelofibrosis / Primary myelofibrosis (disorder) / Myelofibrosis (disorder) / Primary myelofibrosis (morphologic abnormality)

IndicationStatusPhase
DBCOND0044387 (Primary Myelofibrosis (PMF))Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02515630Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)Treatment
NCT02124746Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential ThrombocythemiaTreatment
NCT01236638Extension Study Evaluating the Long Term Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)Treatment